CTRI/2018/02/012256已完成1 期
An Open Labelled, Single Arm Study To Evaluate The Efficacy Of Murvadya Choorna Vati In Pandu Vyadhi W.S.R. To Iron Deficiency Anaemia - NA
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Self
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Pandu Vyadhi will be diagnosed according to subjective & objective parameters.
- •2. Age : 18-60 Yrs. Irrespective of gender, religion, socio-economic status, marital status
- •3. Hb % more than 8 gm% & less than normal i.e. Male - <13g / dl, Female ââ?¬â??
- •< 12g / dl
排除标准
- •1.Endocrine disorders like hypothyroidism, Cushing syndrome, etc.
- •2.Pregnant and lactating lady.
- •3.Patient having tuberculosis, known case of HIV, leprosy, any type of Cancer.
- •4.Patients showing signs and symptoms of internal bleeding, hemorrhoids, menorrhagia or any other bleeding disorder. (Worms, scurvy, puerperal etc.)
研究者
相似试验
尚未招募
3 期
The Effect of Shephalika Patra Kwatha(Medicated decoction) and Gandharva Hastadi(Medicated oil)Taila the Management of Gridhrasi(Sciatica)CTRI/2021/08/035875Dr PALKI BORUAH
尚未招募
Unknown
Marma therapy in sleeplessnessCTRI/2024/07/071601Dr Arya P
进行中（未招募）
1 期
A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 4, 5, or 6 InfectioChronic Hepatitis C Virus Genotype 4, 5 or 6 InfectionMedDRA version: 20.1 Level: PT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestationsEUCTR2015-002349-80-ITABBVIE DEUTSCHLAND GMBH & CO. KG121
招募中
1 期
An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neonates and infants under 6 months of age with confirmed complicated influenza infection.CTIS2024-510663-34-00Glaxosmithkline Research & Development Limited12
进行中（未招募）
1 期
An open label, single arm study to evaluate the pharmacokinetics, safety and tolerability of intravenous (IV) zanamivir in hospitalised neonates and infants under 6 months of age with confirmed influenza infectioInfluenzaEUCTR2019-001588-63-NLGlaxoSmithKline Research & Development Limited12